JAK2 V617F, hemostatic polymorphisms, and clinical features as risk factors for arterial thrombotic events in essential thrombocythemia
- 74 Downloads
A recent mutation located in the JAK2 gene, JAK2 V617F, has been shown to play a transcendental role in the constitutive activation of its tyrosine kinase activity in an important number of cases of Philadelphia negative myeloproliferative disorders (Ph-MPDs). This mutation is a useful tool for diagnosing this diseases because different studies show that this mutation is highly frequent in patients with polycythemia vera (PV) and is present in around 50% of the patients with essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF) . Among the clinical features and phenotypes that characterize Ph-MPD patients, thrombotic and hemorrhagic episodes have been shown to be frequent in these patients. Range values for thrombosis at diagnosis fluctuate between 34% to 39% for PV and 10% to 29% for ET . For hemorrhage, the values are much more variable .
The mechanisms accounting for the increased risk of thrombosis and hemorrhage in Ph-MPD patients are not well...
KeywordsThrombotic Event Polycythemia Vera Thrombophilia Arterial Thrombosis Essential Thrombocythemia
- 5.Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, Borrelli G, Rambaldi A, Barbui T (2007) Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 109:2310–2313PubMedCrossRefGoogle Scholar
- 7.Ruggeri M, Gisslinger H, Tosetto A, Rintelen C, Mannhalter C, Pabinger I, Heis N, Castaman G, Missiaglia E, Lechner K, Rodeghiero F (2002) Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol 71:1–6PubMedCrossRefGoogle Scholar
- 9.Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, Marfisi RM, Finazzi G, Guerini V, Fabris F, Randi ML, De Stefano V, Caberlon S, Tafuri A, Ruggeri M, Specchia G, Liso V, Rossi E, Pogliani E, Gugliotta L, Bosi A, Barbui T (2007) Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110:840–846PubMedCrossRefGoogle Scholar
- 10.Besses C, Cervantes F, Pereira A, Florensa L, Sole F, Hernandez-Boluda JC, Woessner S, Sans-Sabrafen J, Rozman C, Montserrat E (1999) Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 13:150–154PubMedCrossRefGoogle Scholar